Long-Term Osteoporosis Treatment: Transition off Denosumab

Recorded On: 11/20/2023

This topical module includes primer chapter, webinars, and original research from JBMR and JBMR Plus discussing skeletal complications following denosumab cessation and strategies to overcome these complications.

Component List:

  • Primer (10th edition) Chapter 80: Denosumab
  • Webinar: Episode #2 - Education Series on Denosumab Therapy in Osteoporosis and Cancer (Nov 20, 2023)
  • Webinar: Episode #3 - Education Series on Denosumab Therapy in Osteoporosis and Cancer (Jan 11, 2024) 
  • Webinar: Final Episode  - Education Series on Denosumab Therapy in Osteoporosis and Cancer (Jan 22, 2024)
  • JBMR Article: Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures.
  • JBMR Article: Multiple Vertebral Fractures after Denosumab Discontinuation: Freedom and Freedom Extension Trials Addition Post-Hoc Analyses
  • JBMR Article: Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a randomized trial
  • JBMR Article: Zoledronate for the prevention of bone loss in women discotinuing denosumab treatment
  • JBMR Plus Article: Discontinuation of denosumab: Gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine

Key:

Complete
Failed
Available
Locked
Denosumab Therapy in Osteoporosis and Cancer - Episode #2
Open to view video.  |  60 minutes
Open to view video.  |  60 minutes Join us as Bente Langdahl, M.D., Ph.D., Clinical Professor at Aarhus University, and Elena Tsourdi, Ph.D., Senior Consultant at the University Dresden Medical Center, to discuss denosumab discontinuation.
You must register to access.
Denosumab Therapy in Osteoporosis and Cancer - Episode #3
Open to view video.  |  61 minutes
Open to view video.  |  61 minutes In this episode Ghada El-Hajj Fuleihan, MD, MPH, FRCP, Professor of Medicine at American University of Beirut discusses the topics of treating osteoporosis patients with denosumab, candidates for denosumab therapy and ongoing safety concerns and possible complications. This webinar series is supported in part by an educational grant from Amgen Inc.
You must register to access.
Denosumab Therapy in Osteoporosis and Cancer - Final Episode
Open to view video.  |  60 minutes
Open to view video.  |  60 minutes Join us as Monica Fornier, MD, Breast Oncologist at MSK Cancer Center and Michelle McDonald, PhD, Group Leader of the Bone Microenvironment Group at the Garvan Institute of Medical Research discuss basic, translational and clinical aspects of denosumab cessation in the cancer setting. This webinar series is supported in part by an educational grant from Amgen Inc.
You must register to access.
JBMR Article: Denosumab discontinuation in the clinic implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures
Open to download resource.
Open to download resource.
You must register to access.
JBMR Article: Multiple Vertebral Fractures after Denosumab Discontinuation Freedom and Freedom Extension Trials Addition Post-Hoc Analyses
Open to download resource.
Open to download resource.
You must register to access.
JBMR Article: Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis a randomized trial
Open to download resource.
Open to download resource.
You must register to access.
JBMR Article: Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial
Open to download resource.
Open to download resource.
You must register to access.
JBMR Plus Article: Discontinuation of denosumab Gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine
Open to download resource.
Open to download resource.
You must register to access.
Chapter 80 DENOSUMAB
Open to download resource.
Open to download resource.
You must register to access.